Compare

Maze Therapeutics, Inc./$MAZE

1D1W1M3M6MYTD1Y5YMAX

About Maze Therapeutics, Inc.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Ticker
$MAZE
Sector
Health
Primary listing
NASDAQ
Employees
141

MAZE Metrics

BasicAdvanced
$1.7B
-
-$2.67
-
-

What the Analysts think about MAZE

Analyst ratings (Buy, Hold, Sell) for Maze Therapeutics, Inc. stock.
Analyst projections of the future price of Maze Therapeutics, Inc. stock.

Bulls say / Bears say

MZE829 has shown an encouraging early signal: in 12 evaluable patients, the company reported a 36% average reduction in urine albumin, with half achieving a reduction of at least 30%. It also reported no serious adverse events in the interim dataset. (U.S. Securities and Exchange Commission)
MZE782 produced a 42-fold increase in urinary phenylalanine excretion at a Phase 1 dose, and its Phase 2 PKU trial is now enrolling. A separate Phase 2 study in CKD is planned, giving the same drug candidate more than one potential route to value. (U.S. Securities and Exchange Commission)
Maze had $477 million in cash and marketable securities at the end of September and expects funding into 2029. That should support several upcoming clinical milestones without an immediate need to raise capital. (U.S. Securities and Exchange Commission)
The MZE829 efficacy case still rests on an interim readout from just 12 evaluable patients, and the study is not yet a definitive test of benefit. The larger dataset is due in early 2027, so the signal could weaken as more patients are assessed. (U.S. Securities and Exchange Commission)
Maze faces a well-funded rival in Vertex: its pivotal AMPLITUDE study of an APOL1 inhibitor is fully enrolled, with an interim readout expected in early 2027. That programme could establish efficacy or regulatory precedent before MZE829 reaches a pivotal trial. (Biotech Distilled)
Maze remains pre-revenue and loss-making, with its third-quarter net loss widening to $48 million from $30.1 million a year earlier as research and development spending rose. Continued clinical investment will consume cash before any product sales are assured. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 15 Nov 2026.

MAZE Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

MAZE Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.